DiscoverExecutive Insights for Life Sciences InnovatorsAyla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases
Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

Update: 2025-09-05
Share

Description

In this episode of Executive Insights for Life Sciences Innovators, we sit down with Ayla Annac, CEO and Co-Founder of InvivoSciences, a precision medicine company transforming the way therapies are discovered and developed for heart failure and cardiometabolic diseases. Ayla shares insights into InvivoSciences’ innovative platform, the promise of patient-specific models in drug discovery, and the company’s vision for advancing precision medicine.

Learn more at genecoda.com.

Originally recorded and streamed on YouTube Live on April 11, 2025.

Comments 
In Channel
Jim Buck | Medcura – Advancing Surgical Safety Through Innovative Hemostatic Solutions

Jim Buck | Medcura – Advancing Surgical Safety Through Innovative Hemostatic Solutions

2025-10-0731:16

Mike Stocum | Bantam Pharmaceutical – Targeting Cancer Through the Mitochondria

Mike Stocum | Bantam Pharmaceutical – Targeting Cancer Through the Mitochondria

2025-09-2234:53

Mark Stead | Atomic AI – Harnessing Artificial Intelligence and Structural Biology to Unlock RNA Therapeutics

Mark Stead | Atomic AI – Harnessing Artificial Intelligence and Structural Biology to Unlock RNA Therapeutics

2025-09-0837:07

Larry Tiffany | CEO, GenrAb – Developing Fully Human Neuroprotective Antibodies for Neurodegenerative Diseases

Larry Tiffany | CEO, GenrAb – Developing Fully Human Neuroprotective Antibodies for Neurodegenerative Diseases

2025-09-0824:37

Saurabh Johri | Chief Business Officer, Catena Biosciences – Revolutionizing Protein Conjugation for Next-Generation Therapeutics

Saurabh Johri | Chief Business Officer, Catena Biosciences – Revolutionizing Protein Conjugation for Next-Generation Therapeutics

2025-09-0832:50

Darren Dasburg | CEO, Clarus Biologics – Advancing Vaccine and Immunology Innovation with Novel Adjuvant Platforms

Darren Dasburg | CEO, Clarus Biologics – Advancing Vaccine and Immunology Innovation with Novel Adjuvant Platforms

2025-09-0834:37

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

2025-09-0840:35

Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516

Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516

2025-09-0833:48

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

2025-09-0828:43

Rich Shea | CEO, Basking Biosciences – RNA Aptamers for Acute Thrombosis Treatment

Rich Shea | CEO, Basking Biosciences – RNA Aptamers for Acute Thrombosis Treatment

2025-09-0830:16

Dr. Nathan Stasko | CEO, Vast Therapeutics – Nitric Oxide Innovation in Respiratory Health

Dr. Nathan Stasko | CEO, Vast Therapeutics – Nitric Oxide Innovation in Respiratory Health

2025-09-0826:06

Mark Stead | Atomic AI – Harnessing Artificial Intelligence and Structural Biology to Unlock RNA Therapeutics

Mark Stead | Atomic AI – Harnessing Artificial Intelligence and Structural Biology to Unlock RNA Therapeutics

2025-09-0537:07

Larry Tiffany | CEO, GenrAb – Developing Fully Human Neuroprotective Antibodies for Neurodegenerative Diseases

Larry Tiffany | CEO, GenrAb – Developing Fully Human Neuroprotective Antibodies for Neurodegenerative Diseases

2025-09-0524:37

Saurabh Johri | Chief Business Officer, Catena Biosciences – Revolutionizing Protein Conjugation for Next-Generation Therapeutics

Saurabh Johri | Chief Business Officer, Catena Biosciences – Revolutionizing Protein Conjugation for Next-Generation Therapeutics

2025-09-0532:50

Darren Dasburg | CEO, Clarus Biologics – Advancing Vaccine and Immunology Innovation with Novel Adjuvant Platforms

Darren Dasburg | CEO, Clarus Biologics – Advancing Vaccine and Immunology Innovation with Novel Adjuvant Platforms

2025-09-0534:37

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

2025-09-0540:35

Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516

Anna Kazanchyan, MD | CEO, Saghmos Therapeutics – Cardiovascular and Kidney Protection with ST-62516

2025-09-0533:48

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

Charles Swindell | CEO, Glycotest – Advancing Glycoprotein Biomarkers for Liver Disease Detection

2025-09-0528:44

Rich Shea | CEO, Basking Biosciences – RNA Aptamers for Acute Thrombosis Treatment

Rich Shea | CEO, Basking Biosciences – RNA Aptamers for Acute Thrombosis Treatment

2025-09-0530:16

Dr. Nathan Stasko | CEO, Vast Therapeutics – Nitric Oxide Innovation in Respiratory Health

Dr. Nathan Stasko | CEO, Vast Therapeutics – Nitric Oxide Innovation in Respiratory Health

2025-09-0426:06

Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

Ayla Annac | CEO & Co-Founder, InvivoSciences – Precision Medicine for Heart Failure and Cardiometabolic Diseases

GeneCoda® Executive Search